Skip to main content
Equibles

ATHE · Alterity Therapeutics Ltd

Track ATHE — free

Use ATHE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.54 +0.02 (+0.44%) At close · Sep 4
Rebalance outlook locked
Market Cap
$82.67M
Shares
18.21M

ATHE metrics

56 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.54
Market cap
$82.67M

Price action

19 metrics
Price change (1W)
+0.7%
Price change (30D)
-0.2%
Price change (3M)
+16.4%
Price change (6M)
+32.4%
Price change (YTD)
+47.4%
Price change (1Y)
-10.5%
Trailing year
Price change (5Y)
—
52-week high
$5.89
52-week low
$2.92
Change from 52-week high
-22.9%
Change from 52-week low
+55.5%
Annualized volatility
64.6%
Beta
1.3
RSI (14D)
47.8
Price vs SMA 50
-5.3%
Price vs SMA 200
+13.4%
Avg volume (3M)
43,145
Relative volume
0.1
Average dollar volume
$194,711

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
18.21M

Valuation

12 metrics
P / E (TTM)
8.3
Trailing earnings · reciprocal yield 12.1%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
22.3×
reciprocal yield 4.5%
P / book
2.8
reciprocal yield 35.7%
FCF yield
-17.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
12.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2020-12-31

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
269.8%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
$10.02M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-378.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.36

Growth

11 metrics
Revenue growth YoY
+88.6%
Year over year
Net income growth YoY
+7.5%
Revenue (TTM)
$3.71M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-97.6%
Year over year · fewer shares
Revenue CAGR (3Y)
+16.4%
Revenue CAGR (5Y)
+125.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
32.4%
Return on assets
29.7%
Debt / equity
—
Current ratio
14.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$14.04M
Quick ratio
14.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$25.81M
Total assets
$31.82M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.03M
Capital expenditures (TTM)
$7,918
R&D (TTM)
$9.42M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
253.7%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
22
13F filer change QoQ
+7
Institutional ownership
2.2%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1131343 CUSIP 02155X205 13F (30d) 13 filings 13 filers Visit website Investor relations